
Prenatal Steroid Treatment May Improve Survival for Extremely Preterm Infants

WASHINGTON — Steroid treatment before birth appears to improve survival and reduce complications among extremely preterm infants, according to a study funded by the National Institutes of Health.
Antenatal steroid therapy, given to women at risk of preterm delivery, causes the fetal lungs to mature and has been shown to improve survival and reduce complications among infants born from 24 to 34 weeks of pregnancy.
However, previous studies of the treatment for infants born between the 22nd and 23rd week — those at greatest risk for death and disability — were inconclusive, a press release from the NIH said.
The study was conducted by Dr. Sanjay Chawla at Central Michigan University, Mount Pleasant, and Wayne State University, Detroit, and colleagues at 17 other U.S. research institutions.
Their findings first appeared in JAMA Network Open.
Of the mothers of the 431 infants in the study, 110 did not receive the steroid betamethasone, 80 received partial treatment (one dose) and 241 received complete treatment (two doses 24 hours apart).
Of the infants exposed to complete treatment, 53.9% survived until hospital discharge, compared to 37.5% with partial treatment and 35.5% with no treatment.
Compared to infants receiving no treatment, infants exposed to full treatment were 1.95 times more likely to survive and 2.74 times more likely to survive without major complications such as severe bleeding in the brain, severe lung disease (bronchopulmonary dysplasia), cysts in brain, severe inflammation of the intestines (necrotizing enterocolitis) or abnormal blood vessel growth in the retina (retinopathy of prematurity needing treatment).
The study authors concluded that their results provide strong evidence to support giving antenatal steroid therapy to pregnant people at risk for delivery at 22 weeks.
Funding for the research was provided by NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development and National Center for Advancing Translational Sciences.
Dan can be reached at [email protected] and at https://twitter.com/DanMcCue.
In The News
Health
Voting
Research
NATIONAL HARBOR, Md. — It’s not a conference so much as a dream factory that’s transpiring through Friday on the... Read More
NATIONAL HARBOR, Md. — It’s not a conference so much as a dream factory that’s transpiring through Friday on the shores of the Potomac River. Now in its 13th year, the ARPA-E Innovation Summit is a three-day program of lectures, networking events and exhibition hall displays... Read More
WASHINGTON — A temperature-stable, experimental tuberculosis vaccine has been found safe and effective in a clinical phase 1 trial involving... Read More
WASHINGTON — A temperature-stable, experimental tuberculosis vaccine has been found safe and effective in a clinical phase 1 trial involving healthy adults conducted by the National Institute of Allergy and Infectious Diseases. A non-temperature stable form of the candidate previously had been tested in several clinical... Read More
Five years ago, scientist He Jiankui shocked his peers and the world with claims that he created the first genetically edited... Read More
Five years ago, scientist He Jiankui shocked his peers and the world with claims that he created the first genetically edited babies. Now, after serving three years in a Chinese prison for practicing medicine without a license, he faces obstacles and critics as he tries to re-enter... Read More
WASHINGTON — Researchers using a device that stimulates the spinal cord said they successfully restored hand mobility in two stroke... Read More
WASHINGTON — Researchers using a device that stimulates the spinal cord said they successfully restored hand mobility in two stroke patients, allowing them to perform daily life activities like using a fork to eat a meal.While the study was admittedly small — it involved only two... Read More
WASHINGTON — The National Institutes of Health has begun a multi-state clinical trial evaluating an “investigational antiviral” for the treatment... Read More
WASHINGTON — The National Institutes of Health has begun a multi-state clinical trial evaluating an “investigational antiviral” for the treatment of adults hospitalized with COVID-19. The treatment, known as S-217622 or ensitrelvir fumaric acid, was developed in Japan by Hokkaido University and Shionogi & Co., Ltd.... Read More
EDMONTON, Canada — Burning a blend of hydrogen and natural gas to heat homes could reduce carbon emissions by as... Read More
EDMONTON, Canada — Burning a blend of hydrogen and natural gas to heat homes could reduce carbon emissions by as much as 5% per year without having to change existing infrastructure, according to a report out of the University of Alberta. The blended fuel, called hythane,... Read More